

ANNUAL REPORT 2023

GOVERNING BOARD

Executive Committee

Elizabeth Parks, PhD, FTOS	President
Jamy Ard, MD, FTOS	President-Elect
Alison Field, ScD, FTOS	Vice President
Dan Bessesen, MD, FTOS	Past-President
Diana Thomas, PhD, FTOS	Secretary/Treasurer

Board Members

Jaime Almandoz, MD, FTOS	At-Large
Molly Bray, PhD, FTOS	At-Large
Marian Tanofsky-Kraff, PhD, FTOS	At-Large
Sean Wharton, MD, PharmD	At-Large-Canada
Edna Nava-González, PhD	At-Large-Mexico
Fatima Cody Stanford, MD, FTOS	Advocacy/Regulatory
Ellen Schur, MD	Clinical Practice
Ania Jastreboff, MD, PhD, FTOS	Clinical Research
Jeffrey Zigman, MD, PhD, FTOS	Basic/Experimental
Michelle Cardel, PhD, FTOS	Population/Community

TOS ACTIVITIES

- 10 Grand Rounds sessions
- 914 Total participants for Grand Rounds
- 11 Coffee with Professors sessions
- 116 Total participants for Coffee with Professors

POLICY/ADVOCACY

- Produced position statement on medical autonomy
- Co-authored two consensus statements with the International Obesity Collaborative
- Met with the Director of the Food and Drug Administration to discuss two key issues about anti-obesity medications
- Multiple visits with Congressional offices

MEDIA ENGAGEMENT

- 60 media interview requests
- 24 press releases
- 611 Total number of social media posts across Facebook, Twitter (X), LinkedIn and Instagram

OBESITY – The Official Journal of TOS

- 1,556 submissions
- 288 published articles
- Impact Factor – 6.9
- Most cited manuscript: [High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 \(SARS-CoV-2\)](#)

MEMBERSHIP

- Number of members
 - ◆ 1,666 Regular Members
 - ◆ 190 Trainee Members
 - ◆ 339 Student Members
 - ◆ 43 Emeritus Members
- 159 TOS Fellows
- 1,320 New Members

OBESITYWEEK® 2023

- Held Oct. 14 – 17, in Dallas, Texas
- 2,271 participants from 41 countries
- 743 Scientific Sessions
- 710 Abstracts Accepted

PRESIDENTIAL REFLECTIONS

Over the 40-year history of The Obesity Society, 2023 will stand as an extremely impactful year! This was due to the huge step forward taken in development of anti-obesity medications (AOMs) and TOS's role in providing leadership in this field. Across the U.S., the public became aware of AOMs and articles in the lay press were as abundant as research reports published in scientific journals. TOS was highly active in providing education and responding to requests for clinical information, while our members were contributing to the discovery of how these medications work, and simultaneously expanding the understanding of community-based strategies for the prevention of obesity. With regard to education, the attendance of our program, "Coffee with the Professors" grew monthly as we continued to enhance value for our members. On the advocacy front, TOS disseminated its Consensus Statement on Obesity and developed a position statement on patient autonomy. Lastly, under the leadership of Dan Bessesen and Jamy Ard, the Obesity Standards of Care Initiative was launched. With the support of numerous other professional societies, we are providing expert guidance as obesity treatment options increase. Overall, if 2023 was the year members of the public and our profession awakened to the greater use of AOMs, 2024 will bring an expanded clinical understanding of who should be treated and how these medications fit into established lifestyle treatments. It is an exciting time, and we remain energetically committed to our mission - To promote advocacy, education, and research to solve the challenges of obesity. Elizabeth Parks, PhD, FTOS